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Abstract
Background: Intracytoplasmic sperm injection (ICSI) is a component of infertility treatment often
employed when conventional in vitro fertilization is unlikely to be successful. Despite good clinical
results with ICSI, the procedure is typically associated with degeneration of a significant percentage
(approximately 10%) of the treated oocytes. The cause of this degeneration remains unclear.
Speculation that damage caused by oocyte compression during the injection procedure may be
responsible has led to the development of a novel technique known as laser-assisted ICSI. This
procedure involves drilling a small hole through the zona pellucida with a laser prior to sperm
injection. Preliminary studies have suggested that laser-assisted ICSI may dramatically reduce
oocyte degeneration rates. The objective of this study was to examine whether the reported
benefits of laser-assisted ICSI could be verified on a larger, less-selected group of patients.
Methods: Oocytes retrieved from 59 patients scheduled for ICSI were randomly divided into
equal treatment and control groups. Oocytes in the treatment group were inseminated by laser-
assisted ICSI, while oocytes in the control group were inseminated by conventional ICSI. Outcome
variables (oocyte fertilization and degeneration, embryo cell numbers and fragmentation on days 2
and 3, and compaction and blastocyst formation rates) were compared between treatment and
control groups by paired-sample t-test. Subgroup analysis was performed according to zona
pellucida and oolemma breakage patterns.
Results: No significant differences between treatment and control groups were observed for any
of the measured outcome variables. However, fragile zonae pellucidae were associated with
significantly poorer embryo quality, and fragile oolemmas that broke easily upon insertion of the
injection needle were associated with a significantly higher oocyte degeneration rate. Nevertheless,
there were also no between-treatment differences in clinical outcomes within these patient
subpopulations.
Conclusion: Contrary to previous reports based on smaller sample sizes, the results of this study
suggest that there is no benefit of laser-assisted ICSI, either for the general population of ICSI
patients, or for patients prone to zona pellucida or oolemma fragility.
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Background
Intracytoplasmic sperm injection (ICSI), a method of in
vitro fertilization (IVF) in which a single sperm is intro-
duced directly to the cytoplasm of a mature oocyte, has
revolutionized the treatment of male factor infertility.
Since the first reported pregnancies and births in 1992 [1],
ICSI has become the treatment of choice for male factor
infertility. In addition to this original indication, the use
of ICSI has since expanded to a variety of other applica-
tions, such as when fertilization is reduced or absent fol-
lowing conventional in vitro insemination, when using
cryopreserved sperm, and when preimplantation genetic
diagnosis for monogenetic diseases is planned. Some
authors have even advocated the generalized use of ICSI
for all patients undergoing IVF [2]. Intracytoplasmic
sperm injection was used in more than half of all fresh
ART procedures using patients' own eggs performed in the
United States during 2002 [3]. Given this widespread use
of ICSI, any modifications that improve clinical outcomes
of this procedure could benefit a large segment of the
patient population.
Since its inception, ICSI has been performed by the
mechanical penetration of the zona pellucida and the
oolemma by a glass needle through which the sperm is
injected into the cytoplasm. Although the effectiveness of
this procedure has been clearly demonstrated [1,4,5], ICSI
is typically associated with oocyte degeneration rates rang-
ing from 5% to 19% [1,4,6-9]. The reasons for this oocyte
degeneration are unclear. Observations of the zona pellu-
cida of oocytes by scanning electron microscopy revealed
no zona fragmentation during the procedure, and demon-
strated that the injection hole closes immediately after the
needle is withdrawn, with the injection site being nearly
undetectable 15 minutes later [10]. Thus, zona damage
does not appear to be the cause of ICSI induced oocyte
degeneration. The mechanical compression and distor-
tion of the oocyte that commonly occurs, to varying
degrees, during injection is another potential source of
damage leading to oocyte degeneration. Some oocytes
may be more prone to damage from the ICSI procedure
than others. For example, it has been reported that post-
ICSI oocyte degeneration rates are significantly higher for
oocytes with a fragile oolemma that breaks easily upon
insertion of the injection needle than for other oocytes
[6,7].
A novel approach of pre-drilling a hole through the zona
pellucida with a laser prior to ICSI has recently been
reported [11-14]. This alternative approach, called laser-
assisted ICSI, allows the insertion of the sperm injection
needle with less distortion of the oocyte and may there-
fore be less traumatic. Rienzi et al. [11] first reported a
pregnancy using laser-assisted ICSI in a couple with four
previous conventional ICSI failures and poor oocyte sur-
vival. They noted minimal oocyte deformation with the
use of laser-assisted ICSI, and survival of 8 of the 13 met-
aphase II oocytes retrieved and injected. Two small rand-
omized studies of patients with a previous history of high
rates of oocyte degeneration (>20%) following ICSI, or
who produced oocytes with fragile oolemmas, yielded
dramatic statistically significant reductions in oocyte
degeneration rates [12,15] (0.5% versus 16% and 2% ver-
sus 14%, respectively) and improved embryo quality [12]
with the use of laser-assisted ICSI compared to conven-
tional ICSI. Similar benefits have been claimed for piezo-
electric ICSI [16].
The objective of this study was to evaluate the benefits of
laser-assisted ICSI among unselected patients undergoing
in vitro fertilization with ICSI. We describe results of the
largest randomized trial examining laser-assisted ICSI yet
reported, including comparisons of oocyte fertilization
and degeneration rates, cell number and fragmentation
on culture days 2 and 3, and compaction and blastocyst
formation rates.
Methods
Patients were enrolled and treated following discussion of
the study and informed written consent between March
and September of 2004. The Western Institutional Review
Board (WIRB) approved the study protocol (WIRB Pro.
Nr. 20040267).
Indications for ICSI were diagnosis of moderate to severe
male factor infertility or a history of poor conventional
insemination. All patients undergoing IVF with ICSI at
Shady Grove Fertility Reproductive Science Center during
the study period were eligible for participation in the
study, limited to one cycle per patient. The only exclusion
criterion was retrieval of fewer than six mature oocytes.
Mature (Metaphase II, or MII) oocytes from each partici-
pating patient were divided into two equal groups. Half of
each oocyte cohort was assigned to the treatment group
while the other half was assigned to the control group.
Group assignments were allocated according to a compu-
ter-generated randomized series, were kept in sealed enve-
lopes and were unknown to embryologists until after
division of the oocyte cohorts. Treatment assignments
were coded on embryo culture dishes, but effective blind-
ing of embryologists recording fertilization outcomes and
embryo development was not possible, because the hole
in the zona produced by the laser was sometimes visible.
Laser-assisted ICSI was performed on oocytes assigned to
the treatment group using a 1.48 micrometer wavelength
infrared laser (Zilos Laser System, Hamilton Thorne
Research, Beverly, MA). We attempted to replicate the pro-
cedure described in previous reports [11,12] as closely as
possible. A small diameter (5–6 micrometer) channel wasJournal of Experimental & Clinical Assisted Reproduction 2006, 3:5 http://www.jexpclinassistreprod.com/content/3/1/5
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drilled through most of the thickness of the zona pelluc-
ida using 3 to 5 low energy pulses at less than two micro-
seconds pulse duration; the sperm injection needle was
then passed through this channel. Conventional ICSI was
performed according to standard protocols [17] without
laser pre-drilling. Within individual patients, a single
embryologist performed ICSI on all mature oocytes in
both treatment groups. For oocytes inseminated by con-
ventional ICSI, the zona pellucida was graded as normal,
fragile, or difficult according to breakage characteristics
when the injection needle was inserted. Oolemma break-
age patterns (normal, fragile, or difficult) were recorded
for oocytes in both treatment groups. Subgroup analyses
were planned based on these zona and oolemma charac-
teristics.
The primary outcome measure was the percentage of
oocytes that degenerated following the ICSI procedure, as
this was considered the most direct indicator of ICSI-
induced damage. Degenerating oocytes were distin-
guished by dark necrotic cytoplasm and vacuolization at
the time of examination for fertilization, 16–18 hours
after ICSI, when the number of 2 pronucleus (2pn)
oocytes was also recorded. Numbers of cells per embryo
and degree of fragmentation (percentage of total embryo
volume) were recorded on days 2 and 3 of in vitro culture.
Embryos were transferred to patients on either day 3 or
day 5 depending on the number and quality of embryos
available. Non-transferred embryos were monitored
through day 7 for compaction and blastocyst formation.
Total numbers of oocytes and embryos are reported in the
tables along with the per-cycle means for clinical out-
comes. However, it must be emphasized that valid analy-
sis of treatment effects for this experimental design is
based on the per-cycle means, not outcomes per oocyte or
embryo. It is well-known that oocyte and embryo charac-
teristics are much more variable among patients than
within oocyte cohorts. Thus, comparison of outcomes per
oocyte or per embryo violates the assumption of inde-
pendent observations. In this respect, the conclusions of
the first randomized study [12] may be questioned
because the results were evaluated by X2 analysis using
individual oocytes, rather than patients, as the unit of
analysis. The statistical test used in the other prior rand-
omized study [15] was not reported, but p-values are also
consistent with per-oocyte X2 analysis of the data. Valid
estimates of either the size of, or the p-value for, the treat-
ment effects from these two previous studies are not avail-
able.
Paired-sample two-tailed t-tests were used to compare
oocyte fertilization and degeneration rates, numbers of
cells and degree of fragmentation on days 2 and 3, com-
paction and blastocyst formation rates, and numbers of
embryos transferred between conventional and laser-
assisted ICSI treatments. The enrollment goal was set at 60
patients, approximately twice the size of the only previous
randomized study published at the time [12]. Power anal-
ysis was conducted according to Bausell and Li [18]. Pre-
vious examination of oocyte degeneration among patients
undergoing ICSI at our center [19] provided estimates of
the expected mean (10%) and standard deviation (14%)
for oocyte degeneration rates. Based on these parameters
and assuming no correlation between treatment and con-
trol outcomes within patients (i.e. r = 0), this sample size
would provide a minimum of 80% power to distinguish a
reduction in oocyte degeneration with laser-assisted ICSI
of 7.3% (i.e. 2.7% versus 10%), less than half the differ-
ence reported by Abdelmassih et al. [12]. Any correlation
between the treatment and control groups within patients
would increase statistical power. For example, a moderate
correlation of r = 0.4 would result in 95% power to distin-
guish the above difference, and 80% power to distinguish
a reduction in oocyte degeneration of 5.6%.
Results
A total of 80 candidates were enrolled following informed
written consent. Twenty-one of these patients were subse-
quently excluded from the study because fewer than six
mature oocytes were retrieved. From the remaining 59
patients, 775 mature oocytes were retrieved and insemi-
nated in accordance with the experimental design.
Patient age ranged from 22 to 43 years (mean = 34.3 ± 4.0
SD). The majority of couples were diagnosed with male
factor infertility alone (34/59, 58%). Other diagnoses
included endometriosis (n = 4), tubal factor (n = 3), PCO
(n = 3), diminished ovarian reserve (n = 2), ovulation dis-
order (n = 2), and unexplained infertility (n = 7). The
remaining four couples were diagnosed with a combina-
tion of both male and female factor infertility. The overall
mean fertilization rate was 71.1%, with a mean oocyte
degeneration rate of 12.0%. Mean embryo cell number
was 3.0 on day 2 and 5.6 on day 3. Mean degree of embryo
fragmentation was 7.6% on day 2 and 9.8% on day 3.
Embryos were transferred to 44 patients at the cleavage
stage on day 3 (mean = 2.5 embryos per transfer), and to
14 patients at the blastocyst stage on day 5 or 6 (mean =
1.9 embryos per transfer). In only one cycle was no trans-
fer performed due to poor embryo quality. There were 26
pregnancies (44.8% per transfer) with 34 implantations
(24.5% per embryo), based on ultrasound detection of
fetal cardiac activity five to six weeks after embryo transfer,
resulting in 20 live births and 3 spontaneous abortions,
with three pregnancies ongoing at last report.
Clinical outcomes are compared between laser-assisted
and conventional ICSI in Table 1. No significant differ-
ences were observed for any of the measured outcome var-Journal of Experimental & Clinical Assisted Reproduction 2006, 3:5 http://www.jexpclinassistreprod.com/content/3/1/5
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iables. The difference in blastocyst formation rates among
the 14 cycles with blastocyst stage embryo transfer was
nearly statistically significant at an alpha of 0.05. How-
ever, given that this probability estimate does not include
an adjustment for multiple comparisons (thus increasing
the potential for type I error), and none of the many other
comparisons that were made approached statistical signif-
icance, we believe this difference was most likely due to
random chance.
Zona pellucida and oolemma breakage characteristics
were recorded for 50 of the treatment cycles. Normal zona
breakage was observed in all oocytes inseminated by con-
ventional ICSI in 19 of these cycles. The zona was difficult
to puncture in some (11–80% per cycle, mean = 37%) of
the inseminated oocytes in 23 treatment cycles. The zona
was unusually fragile in some (14–50% per cycle, mean
24%) of the inseminated oocytes in 6 cycles. Clinical out-
comes were compared between laser-assisted and conven-
tional ICSI within each of these three subgroups of
patients (Table 2). No differences between the two ICSI
treatments approached statistical significance. In an addi-
tional two cycles (not included in the table) oocytes
exhibiting difficult zona breakage and oocytes with fragile
zonae were both observed.
When the eight cycles with at least one oocyte with a frag-
ile zona were grouped, the degree of embryo fragmenta-
tion on both days 2 and 3 was significantly greater than in
cycles without any oocytes with a fragile zona (14.2% ver-
sus 6.8%, P = 0.018 and 17.0% versus 8.8%, P = 0.029
respectively, t-test). These cycles including oocytes with
fragile zonae also exhibited significantly lower rates of
compaction (23.8% versus 51.5%, P = 0.036), with a
reduced blastocyst formation rate that also approached
statistical significance (15.3% versus 31.8%, P = 0.084).
No other outcome variables were significantly different
between cycles with and without oocytes with fragile
zonae.
Rates of oocyte fertilization and degeneration, and cell
numbers and degree of fragmentation on days 2 and 3,
did not differ significantly between cohorts including
oocytes with difficult to penetrate zonae pellucidae and
cohorts in which all oocytes had normal zonae.
Table 2: Comparisons of laser-assisted versus conventional ICSI outcomes according to zona breakage characteristics.
Normal zona (n = 19) Difficult zona (n = 23) Fragile zona (n = 6)
Laser Conv Laser Conv Laser Conv
Percent 2pn 69.5 (71/106)a 62.9 (68/109)a 73.9 (125/167)a 75.6 (120/161)a 80.2 (30/38)a 79.4 (32/39)a
Percent oocyte degeneration 11.6 (13/106)a 16.1 (16/109)a 10.7 (18/167)a 9.6 (16/161)a 9.4 (3/38)a 12.5 (4/39)a
Cell number, day 3 5.6 5.5 6.0 5.6 5.1 4.8
Percent fragmentation, day 3 10.7 11.0 7.3 7.1 15.7 21.1
Percent compaction 43.2 (19/46)a 59.2 (29/50)a 57.5 (74/109)a 64.2 (69/102)a 29.2 (4/20)a 28.8 (9/26)a
Percent blastocyst 19.3 (7/46)a 30.9 (12/50)a 39.6 (52/109)a 44.7 (47/102)a 20.8 (3/20)a 17.9 (6/26)a
a Numbers in parentheses are total number of oocytes or embryos.
Table 1: Mean clinical outcomes per cycle compared between laser-assisted and conventional ICSI of mature (MII) oocytes, including 
within-patient correlation coefficients (r).
Laser-assisted ICSI Conventional ICSI r Treatment effect (95% CI) P-value
Mature oocytes 6.6 (388)a 6.6 (387)a
Percent 2pn 71.0 (276)a 71.3 (278)a 0.39 -0.3 (-7.2–6.6) 0.94
Percent oocyte degeneration 11.4 (43)a 12.6 (44)a 0.33 -1.2 (-6.2–3.8) 0.63
Cell number, day 2 3.0 2.9 0.46 0.1 (-0.1–0.3) 0.51
Percent fragmentation, day 2 7.0 8.4 0.57 -1.4 (-3.6–0.9) 0.23
Cell number, day 3 5.7 5.5 0.48 0.2 (-0.2–0.5) 0.38
Percent fragmentation, day 3 9.0 10.6 0.64 -1.6 (-4.0–0.7) 0.16
Embryos/ET, day 3, n = 43 1.4 (60)a 1.2 (52)a -0.46 0.2 (-0.2–0.6) 0.32
Embryos/ET, blast, n = 14 1.2 (17)a 0.7 (10)a -0.74 0.5 (-0.2–1.2) 0.15
Percent compactionb 46.5 (121/216)a 54.9 (137/226)a 0.49 -8.3 (-20.2–3.6) 0.17
Percent blastocystb 28.7 (78/216)a 33.1 (83/226)a 0.28 -4.4 (-15.4–6.7) 0.43
Percent compaction, blast ET 90.3 (84/93)a 89.5 (76/85)a 0.32 0.7 (-7.2–8.7) 0.84
Percent blastocyst, blast ET 65.1 (61/93)a 51.7 (48/85)a 0.57 13.5 (-0.1–27.0) 0.051
a Numbers in parentheses are total number of oocytes or embryos.
b Compaction and blastocyst formation rates based on all embryos that were not transferred on day 3.Journal of Experimental & Clinical Assisted Reproduction 2006, 3:5 http://www.jexpclinassistreprod.com/content/3/1/5
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Among all the oocytes for which oolemma breakage pat-
terns were recorded, 25.9% had fragile oolemmas, while
22.7% had oolemmas that were difficult to penetrate.
Both types of oolemma breakage patterns often occurred
in the same oocyte cohort. The percentage of difficult
oolemmas within a cohort was not significantly related to
any observed clinical outcome. However, linear regression
analysis indicated a significant positive relationship
between the percentage of fragile oolemmas in a cohort
and percent oocyte degeneration (P = 0.0026), and a sig-
nificant negative relationship between the percentage of
fragile oolemmas and percent fertilization (P = 0.0033).
The oocyte degeneration rate among cycles (n = 24) with
greater than 30% fragile oolemmas within the oocyte
cohort was twice as high as that of cycles (n = 26) with less
than 30% fragile oolemmas (17.0% versus 8.1%, P =
0.024, t-test). The percentage of fragile oolemmas was not
significantly related to any other clinical outcome. Oocyte
degeneration rates for laser-assisted relative to conven-
tional ICSI were not related to the proportion of fragile
oolemmas in an oocyte cohort (P = 0.14, linear regres-
sion).
Inseminations were performed by one of two embryolo-
gists (AD or JC) for the majority of treatment cycles (n =
29 and 23, respectively). Evidence of a learning curve was
sought by linear regression analysis of the difference
between laser-assisted and conventional ICSI outcomes
according to the case number for each of these two embry-
ologists. There was no evidence of significant change in
relative outcomes over time for either embryologist (ferti-
lization rate P = 0.74 and 0.30, degeneration rate P = 0.25
and 0.88, day 3 cell number P = 0.36 and 0.59, and day 3
fragmentation P = 0.97 and 0.68, respectively).
Transferred embryos were exclusively from the laser-
assisted ICSI treatment group in 12 cycles, resulting in six
pregnancies with four live births and two pregnancies
ongoing at last report. Transferred embryos were exclu-
sively from the conventional ICSI treatment group in
eight cycles, resulting in six pregnancies with four live
births and 2 spontaneous abortions. The remaining 38
transfers included embryos from both treatment groups,
resulting in 14 pregnancies with 12 live births and one
spontaneous abortion, with one pregnancy ongoing at
last report. Among all 26 cycles resulting in pregnancy, 31
of the 60 embryos transferred (52%) were derived from
laser-assisted ICSI. Among the 32 cycles without preg-
nancy, 46 of the 79 embryos transferred (58%) were
derived from laser-assisted ICSI. A X2 comparison indi-
cated that embryos derived from laser-assisted ICSI were
similarly represented in the pregnant and non-pregnant
cycles (P = 0.44).
Discussion
We found no evidence that pre-drilling through the zona
pellucida prior to insertion of the ICSI needle improves
oocyte survival or embryo quality, contrary to the conclu-
sions of two smaller prior studies [12,15]. Rates of oocyte
degeneration and fertilization, cell numbers and fragmen-
tation rates on days 2 and 3, and rates of compaction and
blastocyst formation were similar regardless of ICSI treat-
ment type. The 95% confidence interval for a treatment
effect on oocyte degeneration rates suggests that even if
degeneration rates are lower with laser-assisted compared
to conventional ICSI, the reduction is unlikely to be
greater than 50%, much less than that suggested by the
earlier studies.
However, despite being well designed, evaluation of the
results of these two previous randomized studies is prob-
lematic because both used individual oocytes rather than
patients as the unit of analysis. These 'unit of analysis'
errors are common – a recent systematic review [20] iden-
tified 'unit of analysis' errors in 82% of clinical trials
examined. The use of multiple observations per patient
results in unpredictable bias in treatment effects esti-
mates, and an exaggerated apparent sample size leading to
spuriously low p-values and narrow confidence intervals
[20].
Patient selection may have played a role in the difference
between our results and those of the earlier reports. The
earlier reports included patients selected based on a his-
tory of ICSI with high rates of oocyte degeneration [12] or
fragile oolemmas [15], while ours was based on unse-
lected patients undergoing ICSI. It is therefore possible
that a subset of patients may benefit from laser microma-
nipulation, even if there are no significant benefits to the
general patient population. However, the observed rate of
oocyte degeneration in our control group was only
slightly lower than reported rates of oocyte degeneration
in the control groups of these earlier studies.
Characteristics of the zona pellucida, or possibly the
oolemma, may indicate patients more likely to benefit
from laser-assisted ICSI. It is well known that breakage
patterns of the zona and oolemma can differ greatly
between oocytes. Oocyte compression during the ICSI
procedure is greatest in those eggs with zonae or oolem-
mas that are particularly difficult to penetrate. Laser drill-
ing through a difficult zona pellucida eliminates the
dramatic compression of the oocyte that would otherwise
result from ICSI of such eggs. Fragile oolemmas have been
reported to be associated with higher rates of oocyte
degeneration [6,7]. However, it is more difficult to imag-
ine a benefit of laser-assisted ICSI for a fragile oolemma
because the oolemma is not contacted or manipulated by
the laser during the procedure.Journal of Experimental & Clinical Assisted Reproduction 2006, 3:5 http://www.jexpclinassistreprod.com/content/3/1/5
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We attempted to evaluate the possibility of a benefit
within such subgroups by subdividing our patient popu-
lation according to the zona or oolemma breakage pat-
terns of their oocytes. Although many patients who were
included in this study exhibited zonae with difficult
breakage, resulting in dramatic compression during injec-
tion without laser pre-drilling, we found no evidence of
increased degeneration rates or poorer embryo quality
among these oocytes, and no evidence that they benefited
from the use of the laser. Embryos resulting from cycles
with oocytes with fragile zonae exhibited a higher percent-
age of fragmentation and a reduced rate of compaction
compared to cycles without fragile zonae, but laser-
assisted ICSI did not improve these results.
Blastocyst formation rates appeared to be higher when
oocytes with difficult to penetrate zonae pellucidae were
present in the cohort compared to cohorts in which all
zonae were normal. However, we believe this apparent
relationship is a statistical artifact resulting from the fact
that a much greater proportion of oocytes were transferred
on day 3 in the normal zona group compared to the diffi-
cult zona group (31% versus 14%). Thus, calculations of
compaction and blastocyst formation rates for embryos
not transferred on day 3 (as reported in the tables) include
proportionally fewer of the higher quality embryos in the
normal zona group compared to the difficult zona group.
In addition, it is biologically implausible that the presence
of oocytes with abnormal zonae pellucidae would be
associated with better embryonic development than when
all oocytes within a cohort have normal zonae.
There were also many patients whose oocytes had fragile
oolemmas, and many patients whose oocytes had difficult
to penetrate oolemmas. Oocyte degeneration rates
increased significantly with increasing proportions of
fragile oolemmas, which is consistent with previous
reports [6,7]. However, oocyte degeneration rates for
laser-assisted relative to conventional ICSI did not
decrease as the proportion of such oocytes within a cohort
increased, indicating that laser-assisted ICSI did not
reduce the high rates of degeneration associated with frag-
ile oolemmas. Clinical outcomes were unrelated to the
proportion of oocytes with difficult oolemma penetration
within a cohort.
We do not believe that operator experience was a factor in
our inability to distinguish a beneficial effect of laser
micromanipulation. The lack of any detectable learning
curve supports this contention. All embryologists per-
forming ICSI in this study were highly skilled and had
years of experience performing ICSI and working success-
fully with the laser for embryo manipulation procedures
such as assisted hatching and embryo biopsy. Embryolo-
gists performing the procedure felt that it was relatively
simple and could be performed quickly, although even
with practice the entire process of insemination was still
more time consuming with the addition of the laser
micromanipulation. They also agreed that the compres-
sion of the oocytes during the ICSI procedure was dramat-
ically reduced in the laser-assisted group, as previously
reported [11].
We question the rationale for hypothesizing reduced
oocyte degeneration with laser-assisted ICSI versus con-
ventional ICSI. While laser-assisted ICSI does dramati-
cally reduce oocyte compression, we are aware of no
evidence suggesting increased oocyte degeneration in
association with oocyte compression resulting from either
zonae pellucidae or oolemmas that are difficult to pene-
trate, and our results do not suggest such a relationship.
The one feature that has been clearly associated with
oocyte degeneration rates, a fragile oolemma, seems
unlikely to be responsive to laser pre-drilling of the zona
pellucida because the oolemma is not manipulated by
this procedure.
Although we found no clinical benefit to drilling through
the zona with a laser before sperm injection, we also
found no evidence of harm as a result of the laser micro-
manipulation of oocytes. Oocytes inseminated by laser-
assisted ICSI were as likely to be fertilized successfully as,
and had similar preimplantation developmental potential
to, oocytes inseminated by conventional ICSI. This study
therefore provides evidence for the safety of laser micro-
manipulation of human oocytes via the comparable pre-
implantation development of embryos derived from both
the study and control groups.
Conclusion
In conclusion, the results of this study suggest that there is
no benefit of laser pre-drilling of the zona pellucida over
conventional ICSI with regard to fertilization and embryo
development. Moreover, examination of results according
to the breakage patterns of the zona or the oolemma did
not reveal any subgroups of patients that appeared to ben-
efit from laser-assisted ICSI. Given the increased time
required to add laser pre-drilling to the ICSI procedure,
there appears to be no justification for its use. However,
the potential for benefits within particular patient sub-
groups deserves further study. There was also no evidence
that the laser caused damage that reduced preimplanta-
tion developmental potential.
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